Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan: The PIONEER REAL Japan
The PIONEER REAL Japan, a post-marketing study of semaglutide in Japanese patients with type 2 diabetes, found that more than 70% of patients were taking hypoglycemic agents at baseline and that the main reasons for starting oral semaglutide were glycemic control and weight loss, Dr. Ryo Suzuki and colleagues of Tokyo Medical University reported in the online edition of the Journal of Diabetes Investigation.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
